Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
BTV Highlights: North American Iron, West Red Lake...
Tech 5: US Lifts EDA Restrictions for China,...
CoTec Holdings Corp. Announces Second Closing of Life...
Hempalta Secures 90-Day FCC Forbearance Extension as Company...
BTV Highlights: North American Iron, West Red Lake...
Crypto Market Recap: Crypto Rallies As “Big, Beautiful...
Quimbaya Gold Closes $4 Million Financing and Expands...
Syntheia Signs Definitive Agreement for Call Center Acquisition
Lithium Universe LtdInterview with Executive Chairman
Stallion Uranium to Resume Trading on the TSX-V and...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

by admin October 9, 2024
October 9, 2024
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the ‘Offering’) of 8,437,500 Class A common shares of the Company (the ‘Common Shares’) at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.

The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.

The Offering is expected to close on or about October 10, 2024 (the ‘Closing Date’), subject to the satisfaction of customary closing conditions, including the listing of the Common Shares to be issued under the Offering on the Toronto Stock Exchange (the ‘TSX’) and the Nasdaq Capital Market (the ‘Nasdaq’), receipt of any required approvals of the TSX and Nasdaq, and the entering into of an underwriting agreement between the Company and the underwriter.

The Offering is being made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the ‘SEC’) on July 16, 2024 (the ‘Registration Statement’), and the Company’s existing Canadian short form base shelf prospectus (the ‘Base Prospectus’) dated July 12, 2024. A preliminary prospectus supplement relating to the Offering has been filed with the securities commission in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States, and a final prospectus supplement relating to the Offering (the ‘Supplement’) will be filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.

The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Canaccord Genuity LLC, 1 Post Office Square, Suite 3000, Boston, Massachusetts 02109, Attn: Syndicate Department, or by email at prospectus@cgf.com. Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Offering, whether and when the Offering may close, and the anticipated use of proceeds from the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

For further information, please contact:

Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226119

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

previous post
Libya’s Oil Production: Brent at $77.54. What About WTI? 
next post
Charbone Hydrogene fait appel a un veteran d’Air Liquide avant les premiers revenus du projet phare

You may also like

Raises A$6.22m to Intensify Drilling at Ferke

March 20, 2025

Bold Ventures Identifies New Gold Zone at Its...

December 13, 2024

Jp Cortez: Gold, Silver in Sound Money Renaissance,...

December 12, 2024

Putin Mulls Uranium, Nickel and Titanium Export Limits...

September 13, 2024

GMV Minerals Inc. Completes Initial Drilling at Daisy...

September 27, 2024

Van Eck Opposes Equinox Gold’s US$1.8 Billion Takeover...

March 20, 2025

Top 5 Junior Copper Stocks on the TSXV...

April 17, 2025

Proposed Capital Raising

December 11, 2024

Syntheia

November 20, 2024

Joe Cavatoni: Gold’s Record Run No Surprise, Here’s...

May 7, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • BTV Highlights: North American Iron, West Red Lake Gold Mines, Northisle Copper and Gold, Westport Fuels, US Gold, Orvana Minerals, Avino Silver & Gold, Pasofino Gold, & Mayfair Gold

      July 6, 2025
    • Tech 5: US Lifts EDA Restrictions for China, Apple Explores Third Party AI for Siri

      July 6, 2025
    • CoTec Holdings Corp. Announces Second Closing of Life Offering and Concurrent Private Placement

      July 5, 2025
    • Hempalta Secures 90-Day FCC Forbearance Extension as Company Completes Certification of 2024 Carbon Credits

      July 5, 2025
    • BTV Highlights: North American Iron, West Red Lake Gold Mines, Northisle Copper and Gold, Westport Fuels, US Gold, Orvana Minerals, Avino Silver & Gold, Pasofino Gold, & Mayfair Gold

      July 5, 2025
    Promotion Image

    banner ads

    Categories

    • Business (756)
    • Economy (829)
    • Investing (2,349)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved